Vaccine pre-clinical trial

CD40L

Status: Study completed
Number of volunteers: 30
​​​​​​​Number of visits: 1 or
2

​​​​​​​Study on the impact of a soluble molecule agonist CD40 on the quality of the immune T response with a view to elaborate a vaccination strategy against HIV.

A majority of healthy adults (80-90%) carry viruses such as the Cytomegalovirus (CMV), the Epstein-Barr Virus (EBV) and the Herpes Simplex Virus (HSV). Some cells from the immune system, of which the T memory cells, have developed to some parts of these viruses, called antigens, a response sufficiently strong to be detected directly ex vivo. Also, many individuals’ memory T cells have developed this same type of responses against the tetanus vaccination. T cells coming from subjects with such a response are an ideal model for the study of the capacity of new molecules to enhance the immune T response. The T cells are isolated from the white blood cells. The response of these cells against viral antigens derived from CMV, EBV and HSV, and against the tetanos toxin are assessed with or without the presence of the sCD40L agonist soluble of CD40.

For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

Contact

Division of Immunology and Allergy
Monday to Friday: 8 am - 6 pm
Vaccine and Immunotherapy Center
1011 Lausanne, Suisse
Tél. +41 21 314 1160
Tél. +41 21 314 1163
Fax +41 21 314 1161
 Dernière mise à jour le 28/06/2019 à 08:09